- Acts against: HIV-1; unintended pregnancy
- Formulation: Silicone matrix vaginal ring
- Active ingredient: Dapivirine (ARV); Levonorgestrel (contraceptive hormone)
- Length of action: Three months
- Status: Phase I trial planned for April 2017
Why is the dapivirine-contraceptive ring important?
Offering women a discreet, self-initiated, long-acting product could simultaneously protect them from two of the leading threats to their sexual and reproductive health and help encourage consistent use.
How does the dapivirine-contraceptive ring work?
The ring is made of a flexible silicone matrix polymer and contains dapivirine, an ARV, and levonorgestrel, a contraceptive hormone, both of which are slowly released over the course of 90 days.
Women insert the ring themselves into the vagina and replace it every three months.
What is its development history?
Building on the ring technology used to develop the monthly dapivirine ring, IPM began developing the dapivirine-contraceptive ring in 2011 under a grant from the U.S. Agency for International Development through the President’s Emergency Plan for AIDS Relief. Early prototypes of a 60-day multipurpose ring were developed in collaboration with Particle Sciences and Queens University Belfast. In 2014, after evaluating multiple materials and formulations, IPM and Queens University Belfast targeted a 90-day silicone matrix ring.
What is its clinical history?
IPM is partnering with the Microbicide Trials Network to conduct MTN-030/IPM 041, a Phase I trial of the dapivirine-contraceptive ring, in April 2017. The trial will assess the safety and pharmacokinetics of two different doses of the dapivirine-contraceptive ring, as well as a dapivirine-only ring, in 36 healthy, HIV-negative women who are not pregnant in the United States.
What are the next steps for the dapivirine-contraceptive ring?
MTN-030/IPM 041 is expected to begin in April 2017.
Who is IPM currently partnering with to develop and test the ring?
- ARV license: Janssen Sciences Ireland UC for dapivirine
- Development: Queens University Belfast
- Manufacturing: QPharma
- Clinical trial: Microbicide Trials Network
Where can I learn more about multipurpose rings?
- Our lead ARVs: Dapivirine
- Fact sheet: A Multipurpose Prevention Ring
- Publication: New Technologies for Women’s HIV Prevention: The Payoff for Sustainable Development
- Scientific publications
- Resource: CAMI Health